California State University, San Bernardino

CSUSB ScholarWorks
Theses Digitization Project

John M. Pfau Library

2005

The effect of early psychostimulant treatment on abuse liability
and dopamine receptors
Steven Wayne Villafranca

Follow this and additional works at: https://scholarworks.lib.csusb.edu/etd-project
Part of the Biological Psychology Commons, and the Substance Abuse and Addiction Commons

Recommended Citation
Villafranca, Steven Wayne, "The effect of early psychostimulant treatment on abuse liability and dopamine
receptors" (2005). Theses Digitization Project. 2824.
https://scholarworks.lib.csusb.edu/etd-project/2824

This Thesis is brought to you for free and open access by the John M. Pfau Library at CSUSB ScholarWorks. It has
been accepted for inclusion in Theses Digitization Project by an authorized administrator of CSUSB ScholarWorks.
For more information, please contact scholarworks@csusb.edu.

THE EFFECT OF EARLY PSYCHOSTIMULANT TREATMENT ON ABUSE
LIABILITY AND DOPAMINE RECEPTORS

A Thesis
Presented to the

Faculty of

California State University,

San Bernardino

In Partial Fulfillment
of the Requirements for the Degree

Master of Arts

in
Psychology:

General-Experimental

by

Steven Wayne Villafranca
December 2005

THE EFFECT OF EARLY PSYCHOSTIMULANT TREATMENT ON ABUSE
LIABILITY AND DOPAMINE RECEPTORS

A Thesis
Presented to the

Faculty of

California State University,

San Bernardino

by
Steven Wayne Villafranca
December 2005

Approved by:

Cynthia Crawford, Chair, Psychology

Date

ABSTRACT
Given the large number of children treated with
methylphenidate, it has become increasingly important to
evaluate the possible long-term consequences of

methylphenidate treatment.

To assess whether the

reinforcing properties of drugs of abuse were altered in
adulthood, we administered methylphenidate daily from
postnatal days 11-20 and then measured preference for

morphine during early adulthood using conditioned place

preference.

The number of dopamine D2 receptors was

measured in each rat and the correlation between receptor
number and morphine preference was determined.

Regardless

of sex or pretreatment group, rats exhibited morphineinduced CPP as rats treated with the 5.0 mg/kg morphine had

significantly greater difference scores as compared to rats
treated with saline.

D2 binding densities were not altered

by methylphenidate pretreatment or morphine exposure.

This

evidence implies that preweanling rats exposed to
methylphenidate can alter drug-rewarded behavior and

enhance drug responsiveness in adulthood and suggests that
treating young children (e.g. preschool age) with

iii

methylphenidate may increase the risk of drug addiction
later in life.
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CHAPTER ONE
INTRODUCTION

Overview

In the United States, psychostimulant drugs [e.g.,
methylphenidate (Ritalin) and amphetamine (Dexedrine;

Allderall) are the most commonly prescribed psychotropic
medications given to children (DEA Congressional Testimony,
2000).

Psychostimulant treatment is most commonly used for

Attention Deficit Hyperactivity Disorder (ADHD), but it is
also the preferred treatment for narcolepsy and other
disorders (Wilens & Biederman, 1992) .

It has been estimated

that as high as 15% of school-age children meet the DSM-IV
diagnostic criteria for ADHD (Scahill & Schwab-Stone, 2000).

The large majority of these children are prescribed

methylphenidate (Wilens & Biederman, 1992) .

In fact, the

number of children receiving methylphenidate treatment for

ADHD has doubled every five years since 1971 (Wilens &
Biederman, 1992).

Given the large number of children

treated with methylphenidate, it has become increasingly

important to evaluate the possible long-term consequences of
methylphenidate treatment.
While most studies have concluded that methylphenidate
has few long-term side effects (Borcherding, Keysor,
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Rapoport, Elia, & Amass, 1990; Nolan & Gadow, 1997; Rappley,

1997) , more recent research has found that early exposure to
methylphenidate can alter later behavior in adulthood.
(Andersen et al., 2002; Crawford et al., 2000) .

For

instance, exposing adolescent rodents to methylphenidate
causes an increase in cocaine self-administration and

cocaine-induced conditioned place preference (Achat-Mendes

et al, Brandon, Marinelli, Baker, & White, 2001).

Moreover,

similar results have been demonstrated in humans, as a
recent clinical study found that college students were more

likely to abuse cocaine if they had previously received

methylphenidate during childhood or adolescence (Schenk &

Davidson, 1998).
While the cause of this change in responsivity to

cocaine is unknown, it is possible that changes in dopamine
receptors may be involved.

Repeated treatment with the

psychostimulant methamphetamine during the preweanling
period has resulted in a long-term reduction in the number

of dopamine D2 receptors (Crawford et al.,2000a).

Moreover,

recent imaging studies in humans indicate a relationship
between drug addiction and number of dopamine D2. receptors

(Volkow, Fowler, Wang, & Goldstein, 2002) .

Specifically,

the number of dopamine D2 receptors are predictive of the
rewarding properties of psychostimulants.

2

Subjects with

higher numbers of dopamine receptors did not find acute

treatment with a psychostimulant pleasurable, while subjects
with lower numbers of receptor sites did find the drug

treatment pleasurable.

Since methylphenidate and

methamphetamine share a similar mechanism of action

(Fumagalli, Gainetdinov, Wang, Valenzano, Miller, & Caron,

1999) , it is possible that early methylphenidate treatment
may decrease dopamine binding sites and thus increase the

probability of later drug abuse.

Proposal
It now appears that early methylphenidate treatment may

have long-term effects on behavior.

In particular, early

methylphenidate treatment may increase later vulnerability

to drugs of abuse.

In order to assess whether the

reinforcing properties of drugs of abuse are altered in
adulthood, we will administer methylphenidate daily from
postnatal day (PD) 11-20 and then measure preference for

morphine during early adulthood (i.e., PD 60) using
In addition, rats in this

conditioned place preference.

study will be sacrificed at the end of preference
conditioning and their dorsal striata removed.

The number

of dopamine D2 receptors will be measured in each rat and
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the correlation between receptor number and morphine

preference will be determined.
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CHAPTER TWO

LITERATURE REVIEW

Dopamine Systems

Dopamine is an important catecholamine neurotransmitter
involved in the mediation of reward, motor behavior, and

memory.

Dopamine synthesis begins with the amino acid

tyrosine, which is converted to L-dihydroxyphenylalanine (LDOPA) in the presence of the enzyme tyrosine hydroxylase

(Siegel, Agranoff, Albers, Fisher, & Uhler, 1999).

L-DOPA

is then converted to dopamine by the enzyme DOPA
decarboxylase (or aromatic amino acid decarboxylase)
et al., 1999) .

(Siegel

Conversion of tyrosine to L-DOPA, as well as

L-DOPA to DA occurs in the cytosol (Elsworth' & Roth, 1997).
Free dopamine is then pumped into vesicles by the vesicular

monoamine transporter (VMAT). Dopamine is released by
calcium-dependent exocytosis (Robitaille, Adler, & Charlton,
1990).

During this process, an action potential at the axon

terminal triggers the opening of voltage-gated calcium
channels inducing calcium ion influx and vesicular release

of dopamine (Robitaille, Adler, & Charlton, 1990) .

Newly

synthesized dopamine is preferentially released, although

stored dopamine can be mobilized after repeated
stimulation.

After release, dopamine is primarily
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adenylyl cyclase activity, D2 receptors actually inhibit
adenylyl cyclase activity (Baldessarini & Tarazi, 1996) . As

more receptor subtypes were identified over the years (Dx
through D5) , Clark and White (1987) classified the receptor
subtypes into Di-like ( Dx and D5) and D2-like (D2, D3, and

D4) families.

As research continued, two distinct forms of

the D2 receptor'became evident; D2(iong) and D2(short) •

These D2

receptor subtypes were found to differ by only a 29-amino
acid insertion in the intracellular loop (Smith, Fetsko, &

Wang, 2002).

Clark and White (1987) devised their

nomenclature through an extensive review of studies using
both dopamine agonists and antagonists.
Dopamine agonists, which compete for the same receptor,
cause the same effect as the endogenous neurotransmitter and

stimulates the receptor.

Typical Dx/D5 agonists include SKF

38393, fenoldopam, and dihydrexidine (Gorelova & Yang,

2000).

Although no compounds differentiate Dx and D5

receptors, these receptors differ in other aspects.

The

most widely accepted difference between Dx and D5 receptors

is that D5 receptors display a higher affinity for dopamine
than do Dx receptors (Grandy et al., 1991; Sunahara et al.,

1991; Tiberi et al., 1991).

This observation is in accord

with later research showing that D5 receptors have a
stronger coupling to G-proteins than do Dx receptors (Kimura
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et al., 1995) .

Quinpirole and pergolide represent D2 and D3

selective agonists (Feldman, Meyer, & Quenzer, 1997) .

Quinpirole, however, is more selective for D2 receptors than
D3 receptors.

Conversely, pramipexole, binds with a higher

affinity to D3 receptors than D2 receptors (Bennett &

Piercey, 1999) .

Common D4 agonists consist of CP-226 and

CP-269 (Oak, Oldenhof, & Van Tol, 2000) .

Antagonists also bind to receptor sites, however, they
do not activate the receptor. Instead, antagonists prevent
the endogenous neurotransmitter, and other molecules, from

binding to and stimulating the receptor (Watkins,
Krogsgaard-Larsen, & Honore, 1990) .

Typical Di/D5 receptor

antagonists include SCH 23390, NNC-112, and SCH 39166

(Gorelova & Yang, 2000 ).

Selective D2 receptor antagonists

include haloperidol, sulpiride, spiperone, and YM-09151-2.

Nafadotride and PD 152255 are newly developed D3 receptor
antagonists (Sobrian, Jones, Varghese, & Holson, 2003).

Clozapine is representative of a D4 receptor antagonist (Van

Tol et al., 1991).
Both Di-like and D2-like dopamine receptors are

guanosine triphosphate protein (G-protein) coupled
receptors.

As previously mentioned, D2-like receptors

inhibit adenylyl cyclase activity.

This inhibition is due

to the fact that D2-like receptors are coupled to inhibitory
8

G-proteins (Gi) .

Conversely, Di-like receptors are coupled

to stimulating G-proteins (Gs< Goif) , and increase adenylyl
cyclase activity (Baldessarini & Tarazi, 1996; Herve et al.,

2001).

When activated, Gs proteins stimulate adenylyl

cyclase, which converts adenosine triphosphate (ATP) into

cyclic adenosine monophosphate, or cAMP (Baldessarini &

Tarazi, 1996; Herve et al., 2001) .

In turn, cAMP activates

protein kinase A (PKA), which effects both calcium and

potassium permeability (Siegel et al., 1999).
The highest concentration of Di receptors are found in

the caudate, putamen, nucleus accumbens, olfactory
tubercles, and substantia nigra (Tarazi, Tomosine &

Baldessorini, 1999).

Low concentrations of Dx receptors

also reside in the neocortex, thalamus, cerebellum, and
septum (Wamsley, Alburges, McQuade, & Hunt, 1992) .

D5

receptors, in contrast, are essentially limited to the

hippocampus and hypothalamus (Tarazi, Tomosine &
Baldessorini, 1999).

D2-like receptors have a pattern

similar to Di-like receptors.

For example, D2 and D3

receptors are both found in high concentrations in the

olfactory tubercles and the nucleus accumbens.

In

addition, D3 receptors are found in the islands of Calleja.
D4 receptors are expressed in small quantities in the

striatum (Van Tol et al., 1991), but are fairly prevalent in
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the retina (Cohen, Todd, Harmon, & O'Malley, 1992),cerebral
cortex, amygdala, hypothalamus, and the pituitary (Asghari,

Sanyal, Buchwaldt, Paterson, Jovanovic, & Van Tol, 1995;
Valerio, Belloni, Gorno, Tinti, Memo, & Spano, 1994) .

Dopamine Pathways
Dopamine is found in two major pathways in the central
nervous system: the nigrostriatal and the mesolimbic.

In

the mesolimbic system, dopamine is produced by neurons in

the ventral tegmental area (VTA), which project to
structures such as the prefrontal cortex and the basal
forebrain, including the nucleus accumbens (McBride, Murphy,

& Ikemoto, 1999; Wise & Bozarth, 1984).

The mesolimbic

system is thought to be associated with reward (Bozarth,

1991).

The mesolimbic system is stimulated by natural

means; such as nutriment, predation, and intercourse, as
well as artificially by psychostimulants (Di Chiara, 1999;
Leshner & Koob, 1999; Wise & Bozarth, 1984).

Olds and Milner (1954) provided preliminary empirical
evidence regarding reward and reinforcement in the

mesolimbic system.

These researchers electrically

stimulated the medial forebrain bundle (MFB), and found that
it was rewarding to subjects, as evidenced by repeat bar
pressing.

Additionally, lesioning the MFB disrupts reward

mediated behavior (Wise & Bozarth, 1987).
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Due to the fact

that dopaminergic fibers terminate in the nucleus accumbens,
Bozarth (1991) posits that the nucleus accumbens is the
central location of the rewarding action of drugs of abuse.
Researchers have since found that the activation of the

mesolimbic system results in increased locomotor activity
(Wise & Bozarth, 1987).

The second major dopamine pathway, termed the

nigrostriatal pathway, extends from the substantia nigra to
the dorsal striatum; which contains the caudate and the
putamen (White, 1996).

Dopamine concentrations are at their

highest in the caudate and putamen (Jaber, Robinson,
Missale, & Caron, 1996). The striatum is an important motor

center, as dysfunctions in striatal dopamine have been found

to cause motor disorders such as Parkinson's disease and
Tourette's syndrome (Bennett & Piercey, 1999; Kurlan, Behr,

Medved, & Como, 1988). The dorsal striatum is also

implicated in habit learning such as learning to
automatically perform complex motor tasks, such as driving

an automobile (Di Chiara, 1990).

Moreover, the striatum is

now believed to be a component of a memory circuit
associated with craving (Volkow et al., 2002) and the

formation of habits associated with chronic drug use (White,
1996).
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Morphine and Opioid Systems
Opioids are drugs that are widely used for their

analgesic properties, but are also among the most abused
drugs.

The opioid compounds work by activating a group of

g-protein coupled receptors.

Three types of opioid

receptors have been discovered: mu, delta, and kappa.

All

the opioid receptors are coupled to the inhibitory Gprotein, Gi/O, which inhibits adenylyl cyclase activity and

can directly open K+ and Ca++ channels (Waldhoer, Bartlett, &

Whistler, 2004).

Opioid receptors are distributed

throughout the central nervous system, however, the nucleus

accumbens, caudate putamen, and hypothalamus are

particularly abundant in mu and delta receptors; while kappa
receptors are primarily found in the hypothalamus, small
quantities are also found in the caudate putamen and nucleus
accumbens (Unterwald, Rubenfeld, Imai, Wang, Uhl, & Kreek,

1995; Spangler, Ho, Zhou, Maggos, Yuferov, & Kreek, 1996).
There are four classes of endogenous opioid ligands,

derived from precursor molecules via enzymatic processing,
which activate mu, delta, or kappa receptors (Hertz, 1997).
Beta endorphin is derived from the precursor pro

opiomelanocortin and displays a high affinity for mu
receptors and low infinity for delta receptors.

Proenkephalin gives rise to two types of enkephalins:
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methionine and leucine.

Enkephalins exhibit some

selectivity for delta receptors, while dynorphins show some
selectivity for kappa receptors.

Recent research has

identified a fourth class of endogenous opioid ligand;

endomorphin 1 and 2, which exhibits an extremely high
selectivity for mu receptors (Zadina, Hackler, Ge, & Kastin,

1997).
The opioid system, like the dopamine system, is an

important part of the neural reward circuitry. The

reinforcing actions of opiates are largely mediated by the
mu opioid receptor subtype.

Much like psychostimulants, mu

opioid agonists, such as morphine are readily selfadministered by animals and induce conditioned place
preferences.

A large number of mu opioid receptors reside

in the VTA and nucleus accumbens and when activated increase

the release of dopamine(Di Chiara & North, 1992; Koob,
1992). This mu opioid-induced release of dopamine is

believed to mediate the reinforcing properties of opiates.

However, while some of the rewarding aspects of mu agonists

are dopamine dependent other research has indicated that mu
agonists also use dopamine independent pathways (Di Chiara &

North, 1992; Koob, 1992).

Specially, these studies have

demonstrated that self-administration of morphine is not
blocked by D2 antagonists.

However, other studies suggest
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that some dopamine antagonists (i.e. Di) can block, or
partially block (i.e. 6-OHDA), morphine administration

(Shippenberg & Herz, 1987; Shippenberg & Herz, 1988; Acquas,
Carboni, Leone, & Di Chiara, 1989; De Fonseca, Rubio,

Martin-Calderon, Caine, Koob, & Navarro, 1995).

Methylphenidate and Other Psychostimulants
Overview

Psychostimulants are heterogeneous groups of compounds that

share the ability to increase arousal and activity levels by
activating the sympathetic nervous system, and increasing

levels of extracellular monoamines in the central nervous
system (Creese, 1982).

These compounds have been medically

utilized for their stimulant properties for many years

(Creese, 1982) .

For example, psychostimulants are used to

increase attention levels in ADHD and to increase arousal

levels in narcolepsy (Solomon, White, Parron, & Mendelson,

1979).

In addition to these neuropsychiatric disorders,

psychostimulants are used to treat obesity as they increase

body metabolism and suppress appetite (Martin, Sloan,

Sapira, & Jasinski, 1971; Silverstone, 1981).

Unfortunately, the stimulant properties of these drugs are
also exploited recreationally as psychostimulants are among
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the most addictive and abused class of drugs (Fischman &
Haney, 1999).

Mechanisms- of Action
Cocaine and amphetamine are prototypical

psychostimulants that increase synaptic levels of monoamine

neurotransmitters

(Creese, 1982).

Cocaine increases

synaptic levels of monamines by inhibiting the actions of

dopamine, norepinephrine, and serotonin transporter sites;

however, the reuptake inhibiting actions of cocaine are much
more prominent at dopamine and serotonin synapses (Deutsch &

Schweri, 1994; Kuczenski & Segal, 1997; Pan et al., 1994;

Schenk & Izenwasser, 2002) .

Amphetamine also increases

dopamine levels, as well as extracellular levels of
norepinephrine and serotonin (Kuczenski & Segal, 1997) .
Compared to cocaine, amphetamine has a more complicated

mechanism of action as it increases monoamine levels by

reversing the direction of the monoamine reuptake pumps,
blocking reuptake, and by acting as a monoamine oxidase
inhibitor (Yokel & Wise, 1975).

Amphetamine's ability to

reverse monoamine transporters to release newly synthesized
dopamine and norepinephrine appears to be the most important

of its pharmacological actions (Fumagalli, Gainetdinov,
Wang, Valenzano, Miller, & Caron, 1999).

This releasing

action leaves vast quantities of dopamine and norepinephrine
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free in the synaptic cleft, and produces the 'rush' reported
by drug users (NIDA, 1999).

The psychostimulant, methylphenidate, is structurally
related to amphetamine but has a mechanism of action similar
That is to say, methylphenidate increases

to cocaine.

monoamine levels in the synapse primarily by blocking
transporter sites.

However, methylphenidate, unlike

cocaine, has a very low affinity for the serotonin

transporter, and, consequently, is a poor in vitro inhibitor

of serotonin uptake (Pan et al., 1994; Schenk & Izenwasser,

2002).

Methylphenidate also appears to increase the release

of monoamines using a mechanism similar to amphetamine;
through interaction with monoamine transporters.

Behavioral Effects of Psychostimulants
Acute Effects in Animals

Psychostimulant administration produces a wide range of
behavioral actions.

In rodents, acute psychostimulant

exposure primarily induces locomotor activity at low to

moderate doses while producing intense oral sterotypies at

higher doses (Kelly & Iversen, 1976; Taylor & Snyder, 1971;
Tirelli, Laviola, & Adriani, 2003; Yang, Amini, Swann, &
Dafny, 2003) .

For example, acute injections of low doses of

methylphenidate (under 2.0 mg/kg) produce no significant
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effects on locomotor activity (Yang et al., 2003), while
acute injections of methylphenidate at high doses (2.5 to 40

mg/kg) produce immediate locomotor effects (Yang et al.,
2003).

Similarly, low doses of cocaine, and particularly

amphetamine, cause an increase in locomotor activity, while
higher doses of both psychostimulants induce pronounced

stereotyped behavior (Kelly & Iversen, 1976) .
Acute Effects in Humans

Low doses of acute amphetamine in humans results in
feelings of well-being, increased competence and alertness,

as well as reduced appetite (NIDA, 1998).

Higher doses of

acute amphetamine can cause tremors, sweating, and heart

palpitations in humans (NIDA, 1998).

Low doses of acute

cocaine in humans results in a variety of subjective effects

including: euphoria, talkativeness, increased energy and
mental alertness (NIDA, 1999).

Low doses of acute cocaine

in humans also produces physiological effects such as:
dialated pupils, increased temperature, heartrate, and blood

pressure (NIDA, 1999j .

High doses of acute cocaine results

in bizarre, erratic, and violent behavior (NIDA, 1999).
Acute administration of low doses of methylphenidate in
humans results in elevated blood pressure, tachycardia,

increased respiration, suppressed appetite, and sleep
depravation (NIDA, 2001).

Acute administration of high
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doses of methylphenidate can cause delirium, aggressiveness,

panic states, and hallucinations (Morton & Stockton, 2000) .

Chronic and Repeated Effects
In rodents, repeated intermittent exposure to cocaine
and amphetamine result in a phenomenon called reverse
tolerance or behavioral sensitization (Kalivas & Stewart,

1991).

This phenomenon is characterized by a progressive

and enduring enhancement of the drug-induced behavioral

effects of psychostimulant compounds (Kalivas & Stewart,
1991; Robinson & Berridge, 2001; Sorg & Newlin, 2002).

Behavioral sensitization can be observed after as little as
one drug exposure and can still be detected for at least a
year after the last drug exposure (Kalivas & Stewart, 1991;

Robinson & Becker, 1986)

Much of the interest generated by

behavioral sensitization stems from its utility as an animal
analog of human psychosis (Kalivas & Stewart, 1991) and as a

model of human drug addiction (Davidson, Gow, Lee, &

Ellinwood, 2001) .

Repeated injections of methylphenidate

can also produce behavioral sensitization, with exponential
dosage increases resulting in tolerance (Yang et al.,

2003) .

Marked neurotoxic effects can occur during chronic and
repeated psychostimulant dosing schedules (Davidson, Gow,
Lee, & Ellinwood, 2001).

For example, exposure to high

18

doses of methamphetamine causes long lasting reductions in
dopamine content, tyrosine hydroxylase activity, decreased

dopamine release, and reductions in the number of dopamine
transporters (Bowyer et al., 1992; Eisch, Gaffney,

Weihmuller, O'Dell, & Marshall, 1992; Kokoshka,

Fleckenstein, Wilkins, & Hanson, 2000; O'Dell, Weihmuller, &

Marshall, 1993; Ricaurte, Schuster, & Seiden, 1980; Sabol,
Roach, Broom, Ferreira, & Preau, 2001; Wagner, Ricaurte,
Johanson, Schuster, & Seiden, 1980).

In humans, repeated amphetamine administration produces
paranoia, delusions, hallucinations, and violent behavior
(NIDA, 1998).

Chronic administration of cocaine in humans

also produces several changes in behavior including:
irritability, mood disturbances, restlessness, paranoia, and

auditory hallucinations (NIDA, 1999).

Chronic

administration of methylphenidate can result in psychotic
symptoms similar to amphetamine (Morton & Stockton, 2000) .

Abuse Potential
Both amphetamine and cocaine are highly addictive and

widely abused drugs (Kollins, MacDonald, & Rush, 2001) .

The

National Household Survey on Drug Abuse (2000) estimates
1
that 4.0% of the population have tried methamphetamine at
some point in their lives.

The National Institute on Drug

Abuse (1999) reports that 1.5 million Americans age 12 and
19

older are chronic cocaine users, and 0.9 million abuse
methylphenidate.

Increases in the recreational usage of

methylphenidate has raised concerns regarding its abuse
potential (Johnston, O'Malley, & Bachman, 2003; DEA
Congressional Testimony, 2000).

The illicit use and abuse

of methylphenidate is well known, and has been documented
throughout recent decades.

The illicit use of

methylphenidate among high school seniors increased from

0.1% in 1992 to 2.8% in 1997 (Johnston, O'Malley, & Bachman,

2003).

Methylphenidate is abused orally (Lucas and Weiss,

1971), intranasally (Jaffe, 1991), and through intravenous
administration (Levine, Caplan, & Kauffman, 1986) .

Volkow

and colleagues (1995) found that when methylphenidate is
abused intranasally, the effects are similar to the

intranasal use of amphetamine.

Psychostimulant Neurotoxicity
One proposed mechanism for psychostimulant-induced

toxicity is the production of free radicals.

A free radical

is a molecular species with an unpaired electron.

High-dose

administration of amphetamine and its analogues increase

free radicals (Colado et al., 1997; Fleckenstein et al.,

1997; Giovanni, Liang, Hastings, & Zigmond, 1995).
Molecular oxygen is then released via enzyme degradation and
20

through ngn-enzymatic means (auto-oxidation)

Lee, & Ellinwood, 2001).

(Davidson, Gow,

The enzyme MAO metabolizes

dopamine to DOPAC and hydrogen peroxide.

The resulting

oxygen molecules become highly reactive with other

molecules, hence, they, are termed reactive oxygen species
(ROS).

ROS eventually'reacts with hydrogen peroxide forming

a hydroxyl free radical (Feldman et al., 1997) .

These free

radicals are actually produced during the normal functioning

of cells, however, they are kept in balance by antioxidants.
In the case of a hydroxyl free radical, there is no existing
enzyme reactive enough to remove it (Feldman et al., 1997).
This is dangerous because necrotic cell death can occur

(Davidson et al., 2001).

Necrotic cell death is induced by a chain reaction that

occurs from the reaction between free radicals and a non
radical compound.

Necrosis does not affect individual

cells, but is marked by swelling and inflammation of the
cell in general, as well as the mitochondria (Brown &

Yamamoto, 2 0 03) .

Methamphetamine specifically has the

ability to disrupt the electrical gradient of mitochondrial
plasma membranes.- This eventually results in the cells

contents being ousted, and the cell dying (Davidson et al.,

2001).

In the case of methamphetamine administration,

necrosis may be favored over apoptosis due to ROS formation
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and mitochondrial inhibition (Brown & Yamamoto, 2 0 03) .
Apoptotic cell death is an irreversible mechanical

injury to the cell.

Apoptosis affects individual cells and

is characterized by cell shrinkage and fragmentation.

The

pattern of events in apoptosis is so orderly that the

process if often called programmed cell death.

The process

of apoptosis is intimately intertwined with mitochondria.
Mitochondria produces adenosine triphosphate (ATP), which is
the energy the cell.utilizes to carry out its various
functions.

The activation of apoptosis requires ATP.

Hyperthermia increases the utilization of cellular ATP,
providing a potential basis for amphetamines induction of

necrosis over apoptosis (Madl & Allen, 1995).

The absence

or presence of ATP depletion, in conjunction with the

inhibition of mitochondrial function, may play a role in
determining which type of cell death is induced (Leist,

Single, Castoldi, Kuhnle, & Nicotera, 1997;- Qian, Herman, &
Lemasters 1999).

The mechanisms involved in the switch from

apoptosis to necrosis are not fully understood, but changes

within the mitochondria are indicated (Brown & Yamamoto,

2003).

Dopaminergic neurons have a very high energy demand,

making them particularly sensitive to mitochondrial damage
(Davidson et al., 2001) .

Both apoptotic and necrotic cell

death appear to contribute to psychostimulant neurotoxicity.
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Due to the massive influx of dopamine into the
extracellular space upon psychostimulant introduction, the
second consideration of neurotoxic effects must necessarily
involve neurotransmitter levels.

Excessive monoamine

levels, due to psychostimulant exposure, inevitably lead to

the activation of apoptotic and necrotic mechanisms.
Besides an obvious reduction in dopamine stores, a

downregulation of D2-like receptors is also likely to occur.

This takes place because the remaining receptors must now
compensate for the receptors that are no longer functioning.

As dopaminergic receptors are killed off by the neurotoxic

effects of the drugs, the system becomes downregulated, and
the surviving receptors often become sensitized due to their

now reduced numbers (Nader et al., in press).

The inverse

of this effect is the increase of receptors, known as

upregulation.

The increase in the numbers of receptors is

often accompanied by desensitization.

It has been widely

noted that the neurotoxicity caused by the various

amphetamine analogs results in long-term reductions in
dopamine content (Clausing et al., 1995; Fields, Wichlinski,

Drucker, Engh, & Gordon, 1995).

On the other hand, other

psychostimulants, such as cocaine, have failed to yield
long-term dopaminergic deficits (Capon et al., 1997; Eleven,

Perry, Woolverton, & Seiden, 1990; Yeh & De Souza, 1991;) .
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Ontogeny of Dopamine Systems
Ontogeny of Dopamine Receptors

Determining the precise ontogeny of D± and D2 receptors
has proved difficult as conflicting results of the

development of dopamine receptors have been reported.

However, it is clear that dopamine receptors are present

very early in development as both striatal D2 mRNA and D2
receptor binding have been detected prenatally in rats (De
Vries, Mulder, Schoffelmeer, 1992; Schambra, Duncan, Breese,

Fornaretto, Caron, & Fremeau, 1994) .

Di mRNA has also been

detected as early as gestational day 11, but the receptors
are not detectable prenatally (Broaddus & Bennet, 1990;

Cadoret, Jaber & Bloch, 1993).

Development of both Di and D2

dopamine receptors appears to be complete by the third or
forth postnatal week (Broaddus & Bennett, 1989; De Vries et

al., 1992; Schambra et al., 1994).

Dx receptors, however,

appear to reach adult levels faster than D2 receptors
(Broaddus & Bennett, 1989; Rao, Molinoff, & Joyce, 1991;

Schambra et al., 1994).

During the periadolescent period

(PND 34-46) striatal Di and D2 receptors actually increase
above adult levels and are pruned down once adulthood is

reached (Andersen, 2003; Teicher, Krenzel, Thompson, &

Andersen, 2 0 03) .
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Ontogeny of Psychostimulant-Induced Behavior
Psychostimulants have a multitude of effects in the
developing CNS.

These effects are usually similar to those

found in adults, however, ontogenetic differences do exist.

For instance, acute injections of psychostimulants increase

activity in both adults and pups, while chronic or repeated
dosing schedules produce differential effects (Kalivas &
Stewart, 1991; Robinson & Berridge, 2001).

Specifically,

repeated exposure to psychostimulants causes a progressive
and long-lasting increase in psychomotor activating effects,

a phenomenon which is referred to as behavioral

sensitization (Robinson & Becker, 1986).

In adult rats,

repeated exposure to psychostimulants in general results in
sensitization that can be detected long (i.e., up to a year)
after the cessation of drug administration (Robinson &

Becker, 1986).

In contrast, behavioral sensitization does

not occur until the first week postnatally, moreover,
expression

of the sensitized response is transient upon the

cessation of drug administration.

For example, when either

methylphenidate or amphetamine was administered for 4 or 5
days to rats at PD 10-11 or 16-17, sensitization was

exhibited when tested 1 or 2 days after the cessation of the
dosing regimen, but not 1 week later (McDougall, Collins,

Karper, Watson, & Crawford, 1999; McDougall, Duke, Bolanos,
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& Crawford, 1994) .

The long-term retention of behavioral

sensitization matures progressively and is not complete
until the third postnatal week (Tirelli, Laviola, & Adriani,
2003).

Ontogeny of Psychostimulant Toxicity

High doses of methamphetamine alter dopaminergic
neurons in the adult rat (Davidson et al., 2001) .

Numerous

research studies have shown that high doses of

methamphetamine cause long-term changes in dopamine content,

tyrosine hydroxylase activity, decreased dopamine release,

and reduced numbers of dopamine transporters (Bowyer et al.,
1992; Eisch et al., 1992; Kokoshka et al., 2000; Ricaurte et

al. , 1980; O'Dell et al., 1993; Sabol et al., 2001; Wagner
et al., 1980) .

However, early postnatal exposure to

amphetamine and its analogs have less of an effect on

dopamine levels in comparison with exposure in adults

(Lucot, Wagner, Schuster, & Seiden, 1982; Miller,
O'Callaghan, & Ali, 2000; Wagner et al., 1980).

While the

cause of this differential response to amphetamine
administration is unknown, it is possible that it is due to

an underdeveloped dopaminergic system in rat pups.

For

example, a study comparing the dopaminergic reuptake system

in 5-day old rat pups and adult rats found that the rat pups

were less efficient at removing dopamine from the
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extracellular environment as compared to adult rats (Gazzara

& Andersen, 1997) . This difference in the amount of dopamine
removed is explained by fewer uptake sites in the pups due

to immature nerve terminals (Coulter, Happe, & Murrin, 1996;
Voorn, Kalsbeek, Jorritsma-Byham, & Groenewegen, 198 8) .

In contrast to the inability of amphetamine and
derivatives to cause changes in dopaminergic markers in

young animals, several studies have indicated that early

psychostimulants do have long-term effects when assessed in

adulthood.

For instance it has been found that neonatal

exposure to methamphetamine causes learning impairments on
cognitive tests in adult rats (Vorhees, Ahrens, Acuff-Smith,
Schilling, & Fisher, 1994; Vorhees, Inman-Wood, Morford,

Broening, Fukumura, & Moran, 2000) .

More specifically,

deficits in spatial learning and memory were found after
neonatal methamphetamine treatment (Vorhees et al., 1994;
2000).

This research indicates that the neonatal period, up

to at least PD 20, is extremely sensitive to the effects of

a wide range of psychostimulants.

In addition to the long

term effects on learning and memory, a recent study has
found that preweanling rats exposed to methamphetamine

exhibited a reduction in dorsal striatal D2-like binding
sites and dopamine levels that were still detectable into

adulthood (Crawford et al., 2003).
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Thesis Statement
The most commonly diagnosed childhood behavioral
disorder is ADHD, which is widely treated with the

psychostimulant methylphenidate (Swanson, Seargeant, Taylor,

Sonuga-Barke, Jensen, & Cantwell, 1998).

Recent studies

have indicated that early methylphenidate exposure may have
long lasting effects, espeically on drug responsivity in

adult rats and humans.

Thus, the purpose of this research

project is to determine whether chronic treatment with

methylphenidate during the preweanling period will alter the

reinforcing properties of morphine in young adult rats.

To

determine whether morphine is reinforcing, the condition

place preference (CPP) paradigm was used.

CPP has been used

extensively to measure drug reward (Bardo, Rowlett, &
Harris, 1995) .

The basic premise of CPP holds that when a

drug (US) is paired with contextual cues (CS), the
environmental stimuli acquires the properties of the US.

In

the CPP paradigm, a drug is repeatedly administered in the
same distinctive environment, resulting in the animal
associating the drug effect with the environment.

Each

chamber within the CPP apparatus differs in the visual,

somatosensory, and olfactory cues, which provides distinct

environments (Stolerman, 1992) .

Following the appropriate

number of conditioning trials, the experimental animals are

28

allowed to choose freely between the drug-paired and the

drug-free chamber.

Time spent in the drug-paired chamber,

relative to the drug-free chamber, is indicative of place
preference, and is considered a behavioral measure of a

drug's reinforcing effect.

In the majority of CPP

experiments, the vehicle (typically saline) and the drug are
paired with different compartmental environments (Bardo et

al. , 1995) .

An increase in the amount of time spent in a

chamber that had previously been paired with a drug is

believed to be analogous to drug seeking behavior in human

subjects.

CPP is now believed to model the motivation

elicited by environmental stimuli involved in drug-taking
behavior (Bardo et al. , 1995) .

After preference for the morphine- and saline-paired

compartments are determined, the rats were sacrificed and
the number of dopamine D2 receptors measured.

I predict

that rats given early methylphenidate exposure will (a)
spend a greater amount of time in the morphine-paired
environment than saline-exposed rats and (b) preference for

the drug-paired compartment will be negatively correlated

with the number of dopamine D2 receptors.
If the results showed that early methylphenidate
exposure increases drug preference and decreases dopamine

receptors; it supports the hypothesis that there is a
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biological reason for increased drug use after

methylphenidate treatment.

If the results showed that early

methylphenidate treatment does not change drug preference or

dopamine receptors, this supports the hypothesis that early
methylphenidate treatment does not increase the probability
of later drug use.
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CHAPTER THREE
METHODS AND MATERIALS

Subj ects
Subjects were 108 male and female rats of SpragueDawley descent (Harlan), born and raised at California State

University, San Bernardino.

Litters were culled to ten pups

by 3 days of age, and kept with the dam throughout
behavioral testing.

Pups were kept with the dam until PND

25, at which time they were weaned and placed in group cages

with same-sex litter mates.

Only one rat from each litter

was placed into a particular group.

The colony room was

maintained at 22-24°C and kept under a 12-hr light/dark

cycle.

Behavioral testing was done during the light cycle,

at approximately the same time each day.

Subjects were

treated according to the American Psychological Associations

"Ethical Principles"

(1992), and the Principles of

Laboratory Animal Care (National Institute of Health

Publication # 85-23) .

Apparatus

CPP was done in T-shaped wooden chambers comprised of
three compartments.

The two large end compartments (24 x 30
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x 45 cm) are adjacent to each other and are separated by a
removable partition.

The small compartment (the placement

chamber, 24 x 10 x 45 cm) projects out from the junction

between the large compartments.

A second removable

partition enables rats to enter either of the large
compartments from the placement chamber.

The odor,

flooring, and color of each compartment vary.

One of the

large end compartments has white walls, wire mesh flooring,
and pine bedding, whereas the other large end compartment
has black walls, metal rod flooring, and cedar bedding.

The

placement chamber has a solid wood floor and is painted

gray.

In Vivo Drug Treatment
Starting at PND 10, rats received daily injections of

methylphenidate (0.0, 2.0, or 5.0 mg/kg, ip).

These daily

injections continued for 10 consecutive days.

Morphine-Induced Conditioned Place Preference
Procedure

Following acclimation to handling, a total of 108

sixty-day-old rats from the three pretreatment conditions

were randomly assigned to groups.

A 10-day biased CPP

procedure was used, which included one preconditioning day,
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eight conditioning days (consisting of alternating daily

injections of saline or morphine) and one test-day.

On the

preconditioning day, rats received no injection and were put

in the gray placement chamber of the apparatus.

After rats

entered either the black or white conditioning compartment,'

access to the placement chamber was blocked and rats were
allowed 15 minutes access to the black and white
compartments.

On the conditioning days, rats either

received an injection of morphine (0, 2, or 5 mg/kg, sc) and
were placed in their non-preferred compartment or they
received an injection of saline and were placed in their

preferred compartment.

Initial drug order was

counterbalanced between groups. Conditioning sessions lasted

30 minutes.

On the test day, rats were left uninjected and

given free access to the black and white compartments for 15
minutes.

All conditioning and test days were videotaped and time
spent in the non-preferred compartment and locomotor

activity was scored by experimenters blind to treatment
conditions.

Locomotor activity was assessed by dividing the

two end compartments into four equal quadrants and counting
the number of times each rat crosses into a different

quadrant.

In summary, a 2 x 3 x 3 (sex x pretreatment
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condition x drug group) experimental design was used.

There

was a total of six rats per group.

Membrane Preparation

Immediately following behavioral testing, rats were
sacrificed and their dorsal striata removed.

stored at -80° C until time of assay.

The tissue was

On the assay day,

tissue was thawed on ice and crude membrane homogenates was

made using the following protocol.

Striatal sections from

each rat were homogenized in 100 volumes of 50 mM Tris-HCl
buffer (pH 7.4) for approximately 20 s using a Brinkmann
Polytron.

The homogenates were centrifuged at 20,000 x g

for 20 minutes.

The pellet was resuspended in 100 volumes

of the same buffer and centrifuged again at 20,000 x g for

20 minutes.

The final pellet was suspended in approximately

30 volumes of buffer (pH 7.4).

Protein concentrations for

the final pellet were determined using the Bio-Rad Protein
Assay with BSA as the standard.

Homogenate Ligand Binding Assay

For the D2 receptor binding assay, tissue suspensions
(50-100 jiig/protein) were added to duplicate tubes containing

50 mM Tris, 2 mM NaCl2, 5 'mM KCl, 1 mM MgSO4<
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and 2 mM CaCl2

(pH 7.4) at a final volume of 1 ml.

The tubes also included

[3H]-spiperone in concentrations ranging from 0.05 to 0.6
nM.

Non-specific binding was determined in the presence of

10 /iM (--)-sulpiride.
3 0 minutes at 37° C.

The incubation time for the assay was
Incubation was terminated by vacuum

filtration over glass fiber filters (Whatman GF/B,
pretreated with 0.1% polyethylenimine).

Filters were washed

twice with ice-cold Tris-HCl buffer and radioactivity was

measured by liquid scintillation spectrometry.

Dopamine D2

binding sites (Bmax) and affinity (Kj) was determined using

nonlinear regression using Prism (GraphPad Software).

Statistics
Preference scores (time spent in the non-preferred
compartment on the test day minus the time spent in the same
compartment on the preconditioning day), locomotor activity,

D2 binding data (i.e., Bmax and Kj) was analyzed by separate

2x3x3 (sex x pre-exposure drug x conditioning drug)
analyses of variance (ANOVA's).
post hoc comparisons.

Tukey tests were used for

A Pearson correlation coefficient was

also used to assess the relationship between the preference
for the drug paired room and the number of dopamine D2

binding sites.
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CHAPTER FOUR

RESULTS

Body Weight

During the 10 days of drug administration (i.e., PD 1120), body weight was not significantly affected by

methylphenidate treatment and both males and females

exhibited steady weight gain throughout the injection
procedure [day main effect; F(9, 95) = 2017.17, p < 0.001,
Tukey tests, p < 0.05; see Figure 1].

Body weight, however,

did differ between sexes during the early drug treatment as

males were significantly heavier than females on each
injection day [sex x day interaction; F(9, 95) = 5.51, p <
0.001; Tukey tests, p < 0.05].
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Figure 1. Mean Body Weights During the 10 Days of
Methylphenidate Inj ections.

Rats Were Injected With

Methylphenidate (0, 2.0, or 5.0 mg/kg) from Postnatal Day 11

to Postnatal Day 20.
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Conditioned Place Preference

Regardless of sex or pretreatment group, rats exhibited
morphine-induced CPP, as rats treated with 5.0 mg/kg

morphine had significantly greater difference scores than

saline-treated rats [drug main effect; F(2, 101) = 7.76, p <
0.01; Tukey tests, p < 0.05; see Figure 2].

Rats treated

with the lower dose of morphine (0.5 mg/kg) did not show a

preference for the drug-paired room and sex did not
significantly affect place conditioning. Interestingly, the

preference induced by morphine was altered by

Specifically, rats pretreated

methylphenidate pretreatment.

with 5.0 mg/kg methylphenidate had greater preference scores

than rats treated with saline or 2.0 mg/kg methylphenidate
[post-treatment main effect; F(2, 32) = 4.45, p < 0.02;

Tukey tests, p < 0.05; see Figure 2].
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Figure 2. Mean Preference Score on Test Day. Rats Were Given
Alternating Daily Injections of Morphine (0.0, 0.5, or 5.0

mg/kg) and Saline from Postnatal Day 61. to Postnatal Day 68.

a Indicates a significant difference from rats treated with
0.0 or 0.5 mg/kg morphine (post-treatment main effect) .

b Indicates a significant difference from rats pre-exposed

to 0.0 or 2.0 mg/kg methylphenidate and treated with 5.0

mg/kg morphine.
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Locomotor Activity

Locomotor activity (i.e., line crosses) was assessed on

the first and last day of drug administration in the drug or
non-preferred chamber. Over these two testing periods,

female rats expressed greater levels of locomotor activity

as compared to male rats regardless of methylphenidate

pretreatment or morphine exposure [sex main effect; F(l, 89)

= 5.93, p < 0.05; see Figure 4].

Overall there were no

differences in locomotor activity induced by the saline or

the two doses in morphine for male or female rats.

However,

rats 'treated with 5 mg/kg morphine had similar levels of

locomotor activity on both testing days whereas rats treated
with saline or 0.5 mg/kg morphine had significant reductions

in locomotor activity on the second day of testing [drug by

day interaction; F(2, 89) = 8.68, p < 0.01; Tukey tests, p <
.05; see Figure 3].

Methylphenidate pretreatment also

affected locomotor activity, but only in female rats.
Specifically, female rats pretreated with 2.0 mg/kg
methylphenidate showed significantly less locomotor activity

than similarly treated females pretreated with saline [sex

by pretreatment interaction; F(2, 89) = 4.61, p < 0.02;

Tukey tests, p <.05; see Figure 4] .
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Locomotor Activity
150

0.0 mg/kg

0.5 mg/kg

5.0 mg/kg

Morphine Dose

Figure 3. Mean Locomotor Activity on the First and Last Day
of Drug Administration During Conditioned Place Preference
Conditioning.

During Conditioning, Rats Were Injected with

Either 0.0, 0.5, or 5.0 mg/kg Morphine.
a Indicates a significant difference from similarly treated
rats on day 1.
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Locomotor Activity
300

0.0 mg/kg MPH 2.0 mg/kg MPH 5.0 mg/kg MPH
Pretreatment

Figure 4. Mean Locomotor Activity for Male and Female Rats
During Conditioned Place Preference Conditioning.

a Indicates a significant difference between male and female
rats (sex main effect).

b Indicates a significant difference from female rats
pretreated with 0.0 mg/kg methylphenidate.
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D2 Receptor Binding
Neither D2 binding densities (i.e., Bmax) or affinity
(i.e., Kd) were altered by methylphenidate pretreatment or
morphine exposure.

However, there was a significant

positive correlation between the number of D2 binding sites

and morphine-induced preference scores (r = 0.32, p < 0.05,

see Figure 5).

When this relationship was examined within

each pretreatment group, a positive correlation was only

found for rats in the saline and 5.0 mg/kg methylphenidate

pretreatment groups (r = .62, p < .05; r = .82, p <. 01,
respectively; see Figures 6 and 7), but not for rats

pretreated with 2.0 mg/kg methylphenidate.

Because rats

conditioned with saline and 0.5 mg/kg of morphine failed to

exhibit a conditioned place preference, only rats in the 5.0
mg/kg condition were used in the analysis.
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All MPH Groups

Figure 5. Correlation Between Preference Scores and Number

of Dopamine D2-Like Binding Sites in Rats Pretreated with
Methylphenidate (0.0, 2.0, or 5.0 mg/kg) from Postnatal Day

11 to Postnatal Day 20 and Conditioned with 5 mg/kg
Morphine.
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Saline

Figure 6. Correlation Between Preference Scores and Number

of Dopamine D2-Like Binding Sites in Rats Pretreated with
Saline from Postnatal Day 11 to Postnatal Day 20 and

Conditioned with 5 mg/kg Morphine.
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5 mg/kg MPH

Figure 7. Correlation Between Preference Scores and Number
of Dopamine D2-Like Binding Sites in Rats Pretreated with

5.0 mg/kg Methylphenidate from Postnatal Day 11 to Postnatal
Day 20 and Conditioned with 5 mg/kg Morphine.
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CHAPTER FIVE
DISCUSSION

Overview
The purpose of the present study was to determine

whether chronic treatment with methylphenidate during the
preweanling period would alter the reinforcing properties of
To this end, we determined

morphine in young adult rats.

whether early exposure to methylphenidate would alter
morphine-induced CPP in young adult rats.

In addition, we

also examined whether dopamine D2 binding sites would be
affected by early methylphenidate treatment and if the

number of sites would be correlated with morphine-induced

CPP.

Two hypotheses were made regarding the effects of

early methylphenidate treatment on morphine-induced CPP and
D2 binding sites.

Specifically, it was predicted that rats

pre-exposed to methylphenidate would:

(1) have greater

preference scores as compared to saline pre-exposed rats,

and (2) have fewer D2 receptors than saline exposed rats.
In addition, we hypothesized that there would be a negative
correlation between preference scores and the number of D2
binding sites.
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Effects of Methylphenidate Pre-Exposure
on Morphine-Induced Conditioned Place
Preference
Consistent with numerous other reports, young adult

rats in the present study exhibited a morphine-induced CPP,

as rats spent significantly more time in the intially nonprefered compartment after morphine conditioning as compared

to saline treated rats (for reviews see Bardo et al., 1995;
McBride et al., 1999) . However, this increased preference

for the drug-paired compartment was only observed in rats

conditioned with the high dose of morphine (i.e., 5 mg/kg),
but not the low dose (i.e., 0.5 mg/kg).

This dose effect

was not unexpected as a previous meta-analysis of morphineinduced CPP showed that doses between 1 and 10 mg/kg were

fairly equivalent in producing place preference, while doses
under 1 mg/kg where found to be suboptimal (Bardo et al.,

1995) .

Early exposure to 5 mg/kg methylphenidate, as
orginially predicted, increased the magnitude of the
morphine-induced CPP.

This result suggests that exposure to

methylphenidate during the preweanling period increases the

rewarding value of morphine.

This conclusion is consistent

with studies showing that exposing adolescent rats and mice

to methylphenidate enhances both cocaine self-administration
and cocaine-induced CPP (Achat-Mendes et al., 2003; Brandon
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et al., 2001). However, these results contrast with studies
using preadolescent rats, in which early methylphenidate

exposure decreased cocaine-induced CPP (Andersen et al.,
2002; Carlezon et al., 2003). Taken together, it appears

that age at drug exposure may be critical for determining

the long-term impact of methylphenidate.

Specifically,

methylphenidate exposure during the preadolescent period may
decrease later drug responsiveness, while exposing rats to

methylphenidate during earlier (preweanling) or later

(adolescent) developmental periods may enhance drug

responsiveness.
Interestingly, enhanced morphine-induced CPP was only

observed in rats pre-exposed to the 5 mg/kg dose of
methylphenidate.

This dose effect was not anticipated, as a

previous study using adolescent rats had found that 2 mg/kg
methylphenidate was sufficient to enhance the rewarding

effects of cocaine in a self-administration paradigm.

This

may be suggestive of an age-dependent difference in the

sensitivity to repeated methylphenidate treatment (i.e.,
adolescent rats are more sensitive than preweanling rats).

Alternatively, the self-administration paradigm may be a

more sensitive tool for assessing changes in reward value.
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Early Methylphenidate Pre-Exposure and
D2 Receptors
The present study, as well as the previously mentioned
developmental methylphenidate studies, demonstrated that

early methylphenidate exposure can alter drug-rewarded

behavior.

The neurobiological cause of this alteration in

rewarded behavior is unknown, but changes involving D2

receptors may be responsible.

Evidence for D2 receptor

involvement is threefold: first, several studies using D2
antagonists and D2 knock-out mice have demonstrated the

importance of D2 receptors for drug-rewarded behaviors (Di

Chiara, 1999; Risinger, Freeman, Rubinsten, Low, & Grandy,
2000; Salamone, Cousins, & Snyder, 1997; Noble, 1996; Smith,

Fetsko, Xu, & Wang, 2002); second, early exposure to
methamphetamine (a psychostimulant similar to

methylphenidate) has been reported to cause a decline in D2
receptors that is detectable in adulthood (Crawford et al.,

2003); and third, human imaging studies have demonstrated

that addiction to psychostimulants and other abused drugs is
associated with lower levels of D2 receptors and that the

number of striatal D2 receptors in nondrug-abusing subjects
is negatively correlated with the reinforcing value of
methylphenidate (Volkow et al., 2002; 2004).

Thus, based on

evidence from both the animal and human literature, we
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predicted that D2 receptor binding sites would decline after

early methylphenidate treatment, thus providing a mechanism
for changes in morphine-induced reward.

Moreover, we

hypothesized that the number of D2 receptors would be
negatively correlated with morphine-induced preference

scores.
Our hypothesis regarding changes in D2 receptor sites
was not supported, because we found that the number of D2

receptors was not effected by early methylphenidate
exposure.

Interestingly, however, the number of D2

receptors was positively correlated with morphine-induced
preference scores.

It is not known why morphine-induced CPP

was positively correlated with D2 receptors, while the
rewarding effects of other drugs (i.e., methylphenidate and
alcohol) were found to have negative relationship to D2

receptors is unknown (Volkow et al., 2002; 2004).

It is

possible that exposure to morphine changed the number of D2
binding sites.

Alternatively, the positive association

between D2 binding sites and morphine-induced CPP may be

applicable to only morphine and not other drugs of abuse.
This alternative is supported by a study showing that D2

knock-out mice do not acquire morphine-induced CPP, but they

do show normal cocaine-induced CPP (Smith et al., 2002),
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suggesting that morphine-induced CPP is dependent on D2

receptors while cocaine-induced CPP is not.

Implications and Conclusions
In accordance with previous research, the present study
provides additional evidence that early exposure to

methylphenidate causes behavioral adaptations that persist
into adulthood.

Our results show that exposure to

methylphenidate during the preweanling period increases the

rewarding value of morphine.

These results suggest that

treating young children (e.g. preschool age) with
methylphenidate may be putting them at risk for drug
addiction later in life.

The finding that higher levels of D2 receptors were
associated with morphine-induced CPP may reflect
inadequacies in the current dopamine deficiency theory of

addiction.

The current understanding is that decreased CPP

should be associated with higher levels of D2 receptors and

increased CPP is associated with lower levels of D2
receptors.
findings.

This association does not hold true for our
It may be possible that the theory does not apply

to morphine-induced reward, because greater preference
scores should also be exhibited by rats treated with saline

that have higher levels of D2 receptors.
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In summary, rats pretreated with methylphenidate showed
greater preference scores than saline pretreated rats.

In

particular, early exposure to 5 mg/kg methylphenidate
increased the magnitude of morphine-induced CPP, which
supports our original hypothesis and suggests that exposure

to methylphenidate in the preweanling period increases the

rewarding value of morphine. This finding indicates an agedependent mechanism for assessing long-term drug exposure.
This evidence presupposes that preweanling rats exposed to
methylphenidate can alter drug-rewarded behavior and enhance

drug responsiveness in adulthood and suggests that treating
young children (e.g. preschool age) with methylphenidate may

increase the risk of drug addiction later in life.

Our

second hypothesis was not supported; early exposure to

methylphenidate did not change the number of D2 receptors.

We had originally predicted that an increase in morphineinduced CPP would also be associated with decreased levels

of D2 receptors, our negative finding has implications for

the current understanding of morphine-induced reward in
regards to the dopaminergic theory of addiction.

In

conclusion, the well known link between ADHD and subsequent
substance abuse (Wilens, Biederman, Mick, Faraone, &
Spencer, 1997; Clure, Brady, Saladin, Johnson, Waid, &

Rittenbury, 1999; Schubiner et al., 2000), coupled with the
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relative dearth of controlled studies on the long-term
effects of methylphenidate in young subjects, is emerging as

an important public health issue which requires further
study.
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